Unicycive Therapeutics, Inc. (UNCY) — 8-K Filings

8-K Filings (23)

• 8-K Filing — Apr 6, 2026
• Unicycive Therapeutics Files 8-K with Financial Updates — Mar 30, 2026 Risk: low
  Unicycive Therapeutics, Inc. filed an 8-K on March 30, 2026, reporting on its financial condition and results of operations. The filing includes a press release
• Unicycive Therapeutics Files 8-K Report — Nov 14, 2025 Risk: low
  On November 14, 2025, Unicycive Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No
• Unicycive Therapeutics Files 8-K Report — Oct 28, 2025 Risk: low
  On October 28, 2025, Unicycive Therapeutics, Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 4300 El Cam
• Unicycive Therapeutics Files 8-K — Aug 18, 2025 Risk: medium
  On August 15, 2025, Unicycive Therapeutics, Inc. filed an 8-K report detailing an "Other Event." The filing does not provide specific details about the event it
• Unicycive Therapeutics Files 8-K Report — Aug 15, 2025 Risk: low
  On August 15, 2025, Unicycive Therapeutics, Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 4300 El Cami
• Unicycive Therapeutics Files 8-K — Jul 8, 2025 Risk: low
  On July 7, 2025, Unicycive Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicat
• Unicycive Therapeutics Files 8-K — Jun 30, 2025 Risk: low
  On June 30, 2025, Unicycive Therapeutics, Inc. filed an 8-K report detailing significant corporate events. The filing includes information on the company's resu
• Unicycive Therapeutics Files 8-K with Corporate Updates — Jun 20, 2025 Risk: medium
  On June 17, 2025, Unicycive Therapeutics, Inc. filed an 8-K report detailing several key events. The company announced material modifications to the rights of i
• Unicycive Therapeutics Files 8-K — Jun 10, 2025 Risk: medium
  On June 10, 2025, Unicycive Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indica
• Unicycive Therapeutics Files 8-K on Shareholder Votes & Financials — Jun 9, 2025 Risk: low
  On June 9, 2025, Unicycive Therapeutics, Inc. filed an 8-K report detailing a submission of matters to a vote of security holders and financial statements. The
• Unicycive Therapeutics Files 8-K Report — May 21, 2025 Risk: low
  On May 21, 2025, Unicycive Therapeutics, Inc. filed an 8-K report. The filing indicates that the company is providing information under "Other Events" and "Fina
• Unicycive Therapeutics Files 8-K Report — Jan 7, 2025 Risk: low
  On January 7, 2025, Unicycive Therapeutics, Inc. filed an 8-K report. The filing indicates an 'Other Event' without specifying further details in the provided t
• Unicycive Therapeutics Files 8-K Report — Nov 12, 2024 Risk: low
  On November 11, 2024, Unicycive Therapeutics, Inc. filed an 8-K report detailing other events and financial statements. The company, incorporated in Delaware wi
• Unicycive Therapeutics Closes $10M Public Offering — Sep 25, 2024 Risk: medium
  On September 24, 2024, Unicycive Therapeutics, Inc. announced the closing of its previously disclosed underwritten public offering. The company successfully rai
• Unicycive Therapeutics Faces Delisting Concerns — Jul 15, 2024 Risk: high
  Unicycive Therapeutics, Inc. filed an 8-K on July 15, 2024, reporting a notice of delisting or failure to satisfy continued listing rules. The company's princip
• Unicycive Therapeutics Enters Material Definitive Agreement — Jul 2, 2024 Risk: medium
  On June 26, 2024, Unicycive Therapeutics, Inc. entered into a material definitive agreement. The company, incorporated in Delaware, has its principal executive
• Unicycive Therapeutics Changes Fiscal Year End — Jun 26, 2024 Risk: low
  On June 21, 2024, Unicycive Therapeutics, Inc. filed an 8-K report detailing a change in its fiscal year end from December 31st to June 30th, effective immediat
• Unicycive Therapeutics Files 8-K for Office Location — Jun 25, 2024 Risk: low
  On June 25, 2024, Unicycive Therapeutics, Inc. (UNCY) filed an 8-K report. The filing primarily serves as a notification of their principal executive offices lo
• Unicycive Therapeutics Holds Annual Stockholder Meeting — Jun 20, 2024 Risk: low
  On June 20, 2024, Unicycive Therapeutics, Inc. filed an 8-K report to announce the results of its annual meeting of stockholders. The company's stockholders vot
• Unicycive Therapeutics Files 8-K — Mar 29, 2024 Risk: low
  On March 28, 2024, Unicycive Therapeutics, Inc. filed an 8-K report detailing its financial results and operations. The company, incorporated in Delaware, is in
• Unicycive Therapeutics Files 8-K with Material Agreements — Mar 14, 2024 Risk: medium
  On March 13, 2024, Unicycive Therapeutics, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securiti
• Unicycive Therapeutics Files 8-K for 'Other Events' — Feb 21, 2024 Risk: low
  Unicycive Therapeutics, Inc. filed an 8-K on February 21, 2024, under the 'Other Events' category. The filing indicates a current report pursuant to Section 13

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX